149 related articles for article (PubMed ID: 30890317)
21. The impact of prostate volume and neoadjuvant androgen-deprivation therapy on urinary function following prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Allen ZA; Lief JH; Hinerman-Mulroy A; Galbreath RW
Cancer J; 2004; 10(3):181-9. PubMed ID: 15285928
[TBL] [Abstract][Full Text] [Related]
22. Patient assessment of lower urinary tract symptoms using the international prostate symptom score following low-dose-rate prostate brachytherapy.
Farris JC; Hughes RT; Steber CR; Craven TE; Frizzell BA
Brachytherapy; 2021; 20(6):1107-1113. PubMed ID: 34353749
[TBL] [Abstract][Full Text] [Related]
23. Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer.
Washino S; Hirai M; Saito K; Kobayashi Y; Arai Y; Miyagawa T
Low Urin Tract Symptoms; 2018 Jan; 10(1):57-63. PubMed ID: 27943566
[TBL] [Abstract][Full Text] [Related]
24. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
Mabjeesh NJ; Chen J; Stenger A; Matzkin H
Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
[TBL] [Abstract][Full Text] [Related]
25. Clinical evaluation of tamsulosin in the relief of lower urinary tract symptoms in advanced prostate cancer patients.
Zhang T; Wu H; Liu S; He W; Ding K
Int Urol Nephrol; 2017 Jul; 49(7):1111-1117. PubMed ID: 28409402
[TBL] [Abstract][Full Text] [Related]
26. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
Allen ZA; Merrick GS; Butler WM; Wallner KE; Kurko B; Anderson RL; Murray BC; Galbreath RW
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):981-7. PubMed ID: 15989998
[TBL] [Abstract][Full Text] [Related]
27. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E
BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
[TBL] [Abstract][Full Text] [Related]
28. Long-term urinary quality of life after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):454-61. PubMed ID: 12738320
[TBL] [Abstract][Full Text] [Related]
29. Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute.
Miyake M; Tanaka N; Asakawa I; Hori S; Morizawa Y; Tatsumi Y; Nakai Y; Inoue T; Anai S; Torimoto K; Aoki K; Hasegawa M; Fujii T; Konishi N; Fujimoto K
BMC Urol; 2017 Aug; 17(1):62. PubMed ID: 28806948
[TBL] [Abstract][Full Text] [Related]
30. Comparison of patient-reported acute urinary and sexual toxicity scores in a 6- versus 2-fraction course of high-dose-rate prostate brachytherapy monotherapy.
Ragab O; Banerjee R; Park SJ; Patel S; Zhang M; Wang J; Velez M; Demanes DJ; Kamrava M
J Med Imaging Radiat Oncol; 2018 Feb; 62(1):109-115. PubMed ID: 28856847
[TBL] [Abstract][Full Text] [Related]
31. Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment.
Chang P; Regan MM; Ferrer M; Guedea F; Patil D; Wei JT; Hembroff LA; Michalski JM; Saigal CS; Litwin MS; Hamstra DA; Kaplan ID; Ciezki JP; Klein EA; Kibel AS; Sandler HM; Dunn RL; Crociani CM; Sanda MG;
J Urol; 2017 Feb; 197(2):376-384. PubMed ID: 27593476
[TBL] [Abstract][Full Text] [Related]
32. Triptorelin relieves lower urinary tract symptoms in Chinese advanced prostate cancer patients: a multicenter, non-interventional, prospective study.
He LY; Zhang M; Chen ZW; Yuan JL; Ye DW; Ma LL; Wei H; Yang JG; Chen S; Wan B; Xia SJ; Weng ZL; Kong XB; Wei Q; Jin FS; Zhang XH; Qian WQ; Wang SS; Chen YH; Ma HS; Sun YH; Gao X
BMC Urol; 2018 Mar; 18(1):23. PubMed ID: 29587718
[TBL] [Abstract][Full Text] [Related]
33. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
[TBL] [Abstract][Full Text] [Related]
34. A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer.
Lee WR; McQuellon RP; Harris-Henderson K; Case LD; McCullough DL
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):77-81. PubMed ID: 10656376
[TBL] [Abstract][Full Text] [Related]
35. Assessment of Long-term Changes in Lower Urinary Tract Symptoms in Patients With Prostate Cancer Who Underwent Low-dose-rate Prostate Brachytherapy.
Iinuma K; Nakano M; Kato T; Kato D; Takai M; Maekawa YM; Nakane K; Mizutani K; Tsuchiya T; Ishihara T; Ito M; Matsuo M; Koie T
Urology; 2020 Aug; 142():213-220. PubMed ID: 32416115
[TBL] [Abstract][Full Text] [Related]
36. Two-step transurethral surgery of the prostate and permanent implant brachytherapy for patients with lower urinary tract symptoms and low- to intermediate-risk prostate cancer.
Ivanowicz AN; Wakeman CM; Hubbard RT; DeVoe WB; Haake MR; Teigland CM
Brachytherapy; 2012; 11(6):483-8. PubMed ID: 21937283
[TBL] [Abstract][Full Text] [Related]
37. Predictive Factors for Prolonged Urination Disorder After Permanent
Mori H; Fukumori T; Daizumoto K; Tsuda M; Kusuhara Y; Fukawa T; Yamamoto Y; Yamaguchi K; Takahashi M; Kubo A; Kawanaka T; Furutani S; Ikushima H; Kanayama HO
In Vivo; 2017; 31(4):755-761. PubMed ID: 28652453
[TBL] [Abstract][Full Text] [Related]
38. Prediction of urinary symptoms after 125iodine prostate brachytherapy.
Kelly K; Swindell R; Routledge J; Burns M; Logue JP; Wylie JP
Clin Oncol (R Coll Radiol); 2006 May; 18(4):326-32. PubMed ID: 16703751
[TBL] [Abstract][Full Text] [Related]
39. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
Keyes M; Miller S; Moravan V; Pickles T; McKenzie M; Pai H; Liu M; Kwan W; Agranovich A; Spadinger I; Lapointe V; Halperin R; Morris WJ
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1023-32. PubMed ID: 19111402
[TBL] [Abstract][Full Text] [Related]
40. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
Takahashi R; Miyazato M; Nishii H; Sumino Y; Takayama K; Onzuka M; Oshiro T; Saito S; Fujimoto N; Mimata H; Eto M
Low Urin Tract Symptoms; 2018 Jan; 10(1):76-83. PubMed ID: 29341501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
